UNIV DE BRETAGNE OCCIDENTALE UBO has a total of 13 patent applications. It decreased the IP activity by 100.0%. Its first patent ever was published in 2016. It filed its patents most often in WIPO (World Intellectual Property Organization), China and EPO (European Patent Office). Its main competitors in its focus markets pharmaceuticals, measurement and biotechnology are AMORFIX LIFE SCIENCES LTD, D GEN LTD and THE CORP OF THE TRUSTEES OF THE ORDER OF THE SISTERS OF MERCY IN QUEENSLAND.
# | Country | Total Patents | |
---|---|---|---|
#1 | WIPO (World Intellectual Property Organization) | 4 | |
#2 | China | 2 | |
#3 | EPO (European Patent Office) | 2 | |
#4 | United States | 2 | |
#5 | Canada | 1 | |
#6 | France | 1 | |
#7 | Japan | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Measurement | |
#3 | Biotechnology |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Therapeutic chemical compounds | |
#3 | Peptides | |
#4 | Analysing materials | |
#5 | Measuring distances | |
#6 | Measuring volume |
# | Name | Total Patents |
---|---|---|
#1 | Mignen Olivier | 8 |
#2 | Renaudineau Yves | 7 |
#3 | Debant Marjolaine | 6 |
#4 | Hemon Patrice | 5 |
#5 | Pers Jacques Olivier | 3 |
#6 | Augereau Emmanuel | 3 |
#7 | Delacourt Christophe | 3 |
#8 | Stumpf Andre | 3 |
#9 | Le Dantec Christelle | 2 |
#10 | Jacques Olivier Pers | 1 |
Publication | Filing date | Title |
---|---|---|
WO2021005189A1 | Novel pfar-inhibiting compounds | |
WO2020193450A1 | Substance interacting with c terminal fragment of the stim1 fraction localized to the plasma membrane of the cells, for its use in the treatment of cancers, and in screening and diagnostic methods | |
EP3714942A1 | Monoclonal antibody against stim1 | |
EP3714943A1 | Monoclonal antibody against stim1 | |
US2019154690A1 | Method of treating chronic lymphatic leukaemia and/or systemic lupus erythematosus | |
FR3051902A1 | METHOD FOR DETERMINING THE FLOW OF A COURSE OF WATER | |
CN107771284A | Diagnosed using film STIM 1, prognosis and monitoring chronic lymphocytic leukemia (CLL) and/or systemic loupus erythematosus (SLE) progress method |